JP2006111564A - Platelet aggregation inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a platelet aggregation inhibitor comprising as an effective ingredient a herb or an extract thereof, and a food composition and a medicinal composition containing the same. <P>SOLUTION: The effective ingredient of this platelet aggregation inhibitor is a plant selected from among Hidcote Lavender, Bergamot, Hyssop, Apple Eucalyptus, Lemon Eucalyptus, Salad Burnet, Stevia and Common Soapwort, or an extract thereof. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a platelet aggregation inhibitor containing a plant or an extract thereof as an active ingredient, and particularly to a platelet aggregation inhibitor containing an herb or an extract thereof as an active ingredient.

  Platelets are usually essential cells in the blood that play an important role in stopping blood loss and repairing vascular damage, etc., while platelet coagulation is associated with thrombosis, resulting cerebral or myocardial infarction, It also causes various diseases and symptoms such as stenosis. In recent years, the incidence of these diseases and the like has increased with the increase in fat in the diet, and the demand for antiplatelet agents for the prevention and treatment of these diseases has increased rapidly.

  Aspirin is widely used as an antiplatelet agent because it suppresses the production of thromboxane, which causes platelet aggregation, and has a platelet aggregation inhibitory action. However, aspirin is known to have side effects such as gastrointestinal disorders.

In recent years, it has been found that plant extracts such as herbs have an effect of inhibiting platelet aggregation (Patent Document 1, Non-Patent Document 1). If an edible material such as an herb that can be ingested easily on a daily basis has a platelet aggregation-inhibiting action, a compound having the platelet aggregation-inhibiting action can be ingested from a meal containing these ingredients, which is effective for the prevention and treatment of thrombosis and the like. In addition, it can be more easily consumed as a functional food or a dietary supplement, and absorption can be made more efficient.
JP-A-8-73365 Food and Technology, 2000, No. 9, p. 10-12

  However, as for the platelet aggregation inhibitory action, which is a component extracted from natural products such as plants, the action mechanism is often unclear. Moreover, the present condition is that the naturally derived platelet aggregation inhibitor which has a sufficient platelet aggregation inhibitory effect has not yet been found.

    Accordingly, an object of the present invention is to provide a herb-derived platelet aggregation inhibitor. Another object of the present invention is to provide a food composition and a pharmaceutical composition containing an herb-derived platelet aggregation inhibitor.

  As a edible material, the present inventors focused on herbs that are plants and screened herbal platelet aggregation inhibitory action over a wide range, and the herbal platelet aggregation inhibitory action varies greatly depending on the type of herb. As a result, the present inventors have found that a specific herb has a high platelet aggregation inhibitory action and completed the present invention. That is, according to the present invention, the following means are provided.

  According to one form of the invention, Ruby Basil, Summer Lavender, Hidcote Lavender, French Stoechas Lavender, Apple Mint, Orange Mint (Orange Mint), Water Mint, Cool Mint, Spear Mint, Pepper Mint, Rosemary Tuscanablue, Rosemary Dreamy blue Lemon Thyme, Lemon Balm, Oregano, Bergamot, Hyssop, Cherry Sage, Apple Eucalyptus, Lemon Eucalyptus, Wild Strawberry, salad -Consists of Salad Burnet, Sweet Herb Mexican, Stevia, Roman Chamomile, Common Yarrow, Russian Tarragon and Common Soapwort A platelet aggregation inhibitor comprising as an active ingredient one or more plants selected from the group or an extract thereof is provided.

  In this form, the plants are Hidcote Lavender, Bergamot, Hyssop, Apple Eucalyptus, Lemon Eucalyptus, Salad Burnet, Stevia. It is a preferred embodiment that it is selected from (Stevia) and Common Soapwort.

  Moreover, in the platelet aggregation inhibitor of the present invention, the plant includes Ruby Basil, Summer Lavender, Hidcote Lavender, French Stoechas Lavender, Apple Mint ( Apple Mint, Orange Mint, Water Mint, Cool Mint, Spear Mint, Pepper Mint, Rosemary Tuscanablue, Rosemary Dreamy Blue (Losemary Dreamy blue), Lemon Thyme, Lemon Balm, Oregano, Bergamot, Hyssop, Cherry Sage Is a preferred embodiment, and the plant is Nda (Hidcote Lavender), is a further preferred embodiment be selected from bergamot (Bergamot) and hyssop (Hyssop).

  In the platelet aggregation inhibitor of the present invention, it is also a preferred aspect that the plant is selected from Wild Strawberry and Salad Burnet. Furthermore, it is also a preferable aspect that the plant is selected from Apple Eucalyptus and Lemon Eucalyptus. Furthermore, in the platelet aggregation inhibitor of the present invention, it is also a preferable aspect that the plant is Sweet Herb Mexican, and it is also a preferable aspect that the plant is Stevia.

  In any one of these platelet aggregation inhibitors, the extract is preferably a lower alcohol extract, and a preferred extraction solvent is ethanol. The extract is preferably hot water, water, or a water / organic solvent mixed liquid extract. Furthermore, it is a preferable aspect to use a plant after harvest and before drying as the plant.

  Moreover, it is a preferable aspect that any of these platelet aggregation inhibitors exerts the platelet aggregation inhibitory action expressed using adenosine diphosphate (ADP) as an aggregation-inducing substance.

  According to another embodiment of the present invention, there is provided a food composition comprising any one of the above platelet aggregation inhibitors. According to still another aspect of the present invention, there is also provided a pharmaceutical composition for treating or preventing a disease effective for inhibiting platelet aggregation, comprising an effective amount of any of the above-mentioned platelet aggregation inhibitors. The

  The platelet aggregation inhibitor of the present invention includes Ruby Basil, Summer Lavender, Hidcote Lavender, French Stoechas Lavender, Apple Mint, Orange Mint ( Orange Mint, Water Mint, Cool Mint, Spear Mint, Pepper Mint, Rosemary Tuscanablue, Rosemary Dreamy blue, lemon Lemon Thyme, Lemon Balm, Oregano, Bergamot, Hyssop, Cherry Sage, Apple Eucalyptus, Lemon Eucalyptus, Wild Strawberry (Wild Strawberry), Salad Bar -From Salad Burnet, Sweet Herb Mexican, Stevia, Roman Chamomile, Common Yarrow, Russian Tarragon and Common Soapwort One or two or more plant extracts selected from the group are used as active ingredients.

  The platelet aggregation inhibitor of the present invention contains an active ingredient selected from the specific plant or an extract thereof. All of these plants are herbs. There has been no report that these specific plants have a platelet aggregation inhibitory action or an excellent platelet aggregation inhibitory action. These specific plants are plants that the present inventors have found through screening in a wide range, and from these screenings, other herbs in the same family or in the same genus as the superior herbs are simultaneously found. It has also been found that it cannot be predicted whether it has a platelet aggregation inhibitory effect.

  Since the platelet aggregation inhibitor of the present invention contains, as an active ingredient, an extract of these specific plants that also serves as an edible material, the platelet aggregation inhibitor suitable for continuous and preventive intake from a meal or administration as a drug Will be provided. In addition, although the mechanism in the platelet aggregation inhibitory action by the extract of these specific plants is not clear, it can be said that all are common in the point which is excellent in the inhibitory action of the platelet aggregation which uses ADP as an aggregation inducer.

  Hereinafter, a platelet aggregation inhibitor that is one embodiment of the present invention will be described, and a composition containing the platelet aggregation inhibitor and its use will be described.

(plant)
The plant (herb) used for the present platelet aggregation inhibitor is selected from the group of plants specified above. These plants can be used alone or in combination of two or more.

(Lamiaceae genus: Basil)
Ruby basil (scientific name Ocimum basilicum 'Ruby') is a Labiatae plant, and herbs belonging to the genus are sweet basil (scientific name Ocimum basilicum 'Dark Opal'), lettuce basil (scientific name Ocimum basilicum) 'Crispum'), cinnamon basil (scientific name Ocimum basilicum 'Cinnamon'), licorice basil (scientific name Ocimum basilicum 'Licorice'), purple russell basil (scientific name Ocimum basilicum 'Purple Ruffles'), bush basil (scientific name Ocimum basilicum' Mini , Lemon Basil (scientific name Ocimum basilicum 'Lemon'). Ruby basil has the highest platelet aggregation inhibitory activity among these basil.

(Lamiaceae Lavandula: Lavender)
Hidcote Lavender (scientific name: Lavandula angustifolia 'Hidcote'), Summer Lavender (scientific name: Lavandula angustifolia 'Summer'), French Lavender (scientific name: Lavandula stoechas f.leucantha), and French St. Ecus Lavender (scientific name: Lavandula stoechas) The herbs include yellow flower lavender (scientific name: Lavandula angustifolia 'Yellow Flower'), spike lavender (scientific name: Lavandula antififolia), and English lavender (scientific name: Lavandula angustifolia). Among these, Hidd Coat Lavender, Summer Lavender, French Lavender and French Stoke Ecus Lavender have good platelet aggregation inhibitory activity, and French St Ecus Lavender and Hidd Coat Lavender are superior, Coat vendors have the highest platelet aggregation inhibitory activity.

(Lamiaceae genus: mint)
Apple mint (scientific name Mentha suaveolens), water mint (scientific name Mentha aquatica), orange mint (scientific name Mentha x piperita var citorata 'Orange'), cool mint (scientific name Mentha arvensis var agrestis), spearmint (scientific name Mentha spicata), peppermint (scientific name) Mentha × piperita) is a Labiatae plant, and herbs belonging to the same family include eau de cologne mint (scientific name Mentha × piperita 'Citrata') and pineapple mint (scientific name Mentha suaveolens 'Variegata'). Among these, apple mint, water mint, orange mint, cool mint, spearmint, and peppermint have good platelet aggregation inhibitory activity. In other words, eau de cologne mint and pineapple mint showed almost no platelet aggregation inhibitory activity, but all of these mint showed good platelet aggregation inhibitory activity, among which apple mint, water mint and cool mint were excellent in inhibiting platelet aggregation. Has activity.

(Lamiaceae genus: Rosemary)
Rose Marie Dreamy Blue (scientific name Rosmarinus officinalis 'Dreamyblue'), Rose Marito Scana Blue (scientific name Rosmarinus officinalis 'Tuscan Blue') is a Labiatae plant, and as a herb of the same genus, rosemary wood (scientific name Rosmarinus officinalis 'Wood') There is. In the genus Rhododendron, Rose Marie Dreamy Blue and Rose Marito Scana Blue have good platelet aggregation inhibitory activity, and among them, Rose Marie Dreamy Blue is excellent.

(Other Lamiaceae plants)
Lemon thyme (scientific name: Thymus × citriodorus), lemon balm (scientific name: Melissa officinalis), oregano (scientific name: Origanum vulgare), bergamot (scientific name: Monarda didyma), hyssop (scientific name: Hyssopus officinalis), cherry sage (scientific name: Salvia greggii) It is. Among a number of Lamiaceae plants, such as Sweet Marjoram (scientific name: Origanum majorana), Pineapple Sage (scientific name: Salvia elegans 'Scarlet Pineapple'), Amethyst Sage (scientific name: Salvia leucantha), and Clary Sage (scientific name: Salvia sclarea). In particular, bergamot and hyssop have remarkably excellent platelet aggregation inhibitory activities.

(Pinaceae Eucalyptus: Eucalyptus)
Apple eucalyptus (scientific name Eucalyptus cinerea) and lemon eucalyptus (scientific name Eucalyptus citriodora) are both myrtaceae plants, but both have good platelet aggregation inhibitory activity. Among them, lemon eucalyptus has remarkable platelet aggregation inhibitory activity.

(Asteraceae)
Stevia (scientific name: Stevia rebaudiana), Roman chamomile (scientific name: Chamemelum nobile), Common Yarrow (scientific name: Achillea millefolium), and Russian tarragon (scientific name: Artemisia dracunculoides) are all asteraceae plants. The herbs include Echinacea (scientific name Echinacea purpurea) and chicory (scientific name Cicholium intybus), but these herbs have only weak platelet aggregation inhibitory activity or, on the contrary, have platelet aggregation promoting action. Stevia, Roman Chamomile, Common Yarrow, and Russian Tarragon show good platelet aggregation inhibitory activity. Among them, Russian tarragon and stevia are excellent, and stevia is even better.

(Rosaceae)
Wild strawberry (scientific name: Fragaria vesca) and salad barnet (scientific name: Sanguisorba minor) are rosaceae plants, both of which have a good platelet aggregation inhibitory activity, among which salad burnet has an excellent platelet aggregation inhibitory activity.

(Anemoneaceae)
The sweet herb Mexican (Lippia dulcis) is a scorpionaceae plant, and the herb includes Lemon Verbena (scientific name Lippia citriodora). Sweet herb Mexican has an excellent platelet aggregation inhibitory action.

(Dianthus plant)
Common soap wate (scientific name: Saponaria officinalis) is a dianthus plant and has excellent platelet aggregation inhibitory activity.

  The active ingredient of the platelet aggregation inhibitor of the present invention is an extract of these specific plants. As long as the active ingredient is contained in these plants as the raw material in a form contained in the extract, all or part of the herb as the raw material can be used as the active ingredient.

  Therefore, in one form of the platelet aggregation inhibitor of the present invention, as an active ingredient, fruits, seeds, seed coats, flowers, stems, leaves, roots and / or rhizomes which are all or a part of these plants are used as they are, or The processed material which gave the process of pulverizing, drying, etc. can be contained. In plants, it is usually preferable to use leaves. Furthermore, the active ingredient of the present platelet aggregation inhibitor can be the whole plant, a part thereof, or a plant extract using a processed product as a raw material or a fraction obtained from the extract.

  As a plant as a raw material, a dried plant (dried herb) can be used in addition to a plant after harvesting and before drying (fresh herb), but fresh herb is preferably used. In the present specification, the plant after harvesting and before drying (fresh herb) means a plant that has not been dried for 14 days after harvesting by a normal method and has not been dried. It also includes those that have been thawed at any time after freezing before the passage of the day. More preferably, it is before 72 hours have passed since harvesting. Here, “drying” means an operation of actively removing moisture in a state other than the so-called storage or storage state, such as sun drying or drying with an apparatus.

  Extraction of the active ingredient from the plant can be performed, for example, by chopping the plant and mixing and stirring with the extraction solvent, or by crushing or grinding with the extraction solvent. When a fresh herb is used, it is shredded, and immediately or immediately mixed with an appropriate extraction solvent and then stirred and further ground or ground for extraction. The extraction solvent is not particularly limited, and water, methanol, ethanol, isopropyl alcohol, n-butyl alcohol, tert-butyl alcohol, lower primary alcohols of amyl alcohol, 1,3-butylene glycol, propylene glycol and other polyvalent solvents. Alcohols, ketones such as acetone and methyl ethyl ketone, lower alkyl esters such as methyl acetate and ethyl acetate, and solvents such as hexane, chloroform and dichloromethane can be used. These solvents can be used alone or in combination of two or more. Preferred organic solvents are lower alcohols, especially ethanol. As the extraction solvent, water, hot water or a mixture of the above organic solvent and water can be preferably used, and water and hot water can be more preferably used. In addition, the ratio of the extraction solvent with respect to an extraction raw material can be suitably determined without limitation.

  The extraction method is not particularly limited, and these plant raw materials are immersed in an extraction solvent, or extracted as necessary by extraction at room temperature, under heating or cooling, and filtering to remove the solid content. A liquid can be obtained. The extraction under heating or cooling can be performed as long as the extraction solvent can maintain a liquid state, but can also be performed using a reflux device or the like as necessary. The extract thus obtained can be used as it is, but can be concentrated or dried as necessary. Furthermore, it can also refine | purify using the normal refinement | purification means using a column etc. as needed.

  The extract thus obtained has various forms such as a solution, a paste, and a powder, but has an inhibitory action on platelet aggregation. The platelet aggregation inhibitory action can be measured by various methods using a commonly used aggregation inducer such as ADP, collagen, arachidonic acid, etc. As the present platelet aggregation inhibitor, at least platelet aggregation by ADP is suppressed. It is preferable.

  The platelet aggregation inhibitor of the present invention is related to various vascular diseases such as brain, heart, peripheral and other diseases of humans or non-human animals, which are associated with platelet aggregation inhibitory action and are considered to be effective. It is preferably used for applications that are administered or ingested for the purpose of prevention or symptom improvement. In particular, since the present platelet aggregation inhibitor is derived from a food factor, it is preferably used for applications that are continuously administered or ingested. In addition, it is preferably used for applications that are ingested continuously for the purpose of maintaining or improving the health of humans or non-human animals.

  The present platelet aggregation inhibitor is useful not only for research purposes but also as pharmaceuticals, quasi-drugs, foods, beverages, dietary supplements (supplements), feeds and veterinary drugs, or raw materials thereof.

(Composition)
The composition containing the present platelet aggregation inhibitor can have various forms depending on the application.
(Pharmaceutical composition)
According to the present platelet aggregation inhibitor, a pharmaceutical composition is provided. According to the pharmaceutical composition containing the present platelet aggregation inhibitor, therapeutic agents for various vascular diseases and other diseases such as brain, heart, and extinction of human or non-human animals, which are effective in inhibiting platelet aggregation. Or prophylactic drugs are provided. This pharmaceutical composition can be used as a so-called antiplatelet agent, and target diseases include myocardial infarction due to thrombosis, ischemic heart disease such as angina, cerebrovascular disorders including stroke such as cerebral infarction, peripheral arteries, etc. Peripheral vascular disorder, economy class syndrome and inflammation associated with thrombosis, and coronary restenosis.

  The pharmaceutical composition can be obtained by combining the present platelet aggregation inhibitor and an acceptable known pharmaceutical carrier in combination. For formulation, the present platelet aggregation inhibitor is blended with a pharmaceutically acceptable liquid or solid carrier, and if necessary, a solvent, a dispersant, an emulsifier, a buffer, a stabilizer, an excipient, a binder, a disintegrant, It is achieved by adding a lubricant or the like to form a solid agent such as a tablet, granule, powder, powder or capsule, or a liquid agent such as a normal solution, suspension or emulsion. Moreover, it can also be set as the use-soluble solid product which can be made into a liquid state by appropriate addition at the time of use, and can also be used as an external preparation.

  The pharmaceutical carrier can be selected according to the administration form and dosage form of the pharmaceutical composition. In the case of an oral preparation, for example, starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salt, etc. are used. In preparation of the oral preparation, a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a corrigent, a colorant, a fragrance and the like can be further added. On the other hand, in the case of parenteral agents, according to conventional methods, the present blood aggregation inhibitor is distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, It can be prepared by dissolving or suspending in propylene glycol, polyethylene glycol or the like, and adding a bactericidal agent, stabilizer, tonicity agent, soothing agent, etc. as necessary. Alternatively, it can also be provided as a parenteral preparation such as an injection dissolved at the time of use that can be dissolved by these diluents at the time of use.

  The pharmaceutical composition of the present invention is administered in an appropriate dosage form such as internal use, external use, injection, drip, infusion, aspiration, etc., depending on the dosage form. Injections can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally, and external preparations include suppositories. In addition, for example, the composition can be administered by being directly applied to a subcutaneous disease or degeneration site by application, spraying, injection or the like.

  The dosage when the pharmaceutical composition is administered for therapeutic or prophylactic purposes is appropriately set according to the formulation form, administration method, purpose of use and age, weight, and symptoms of the patient applied thereto, and is not constant. Generally, the amount of the platelet aggregation inhibitor used in the present invention contained in the preparation (dry solid content of the extract) is preferably 0.01 to 400 mg / kg body weight per day for an adult, more preferably 0. .2 to 200 mg / kg body weight. About 10 times the dry solid content of the extract is the dry plant weight, and about 100 times the amount corresponds to the plant weight before drying. The dosage varies depending on various conditions in addition to the type of platelet aggregation inhibitor to be used, so an amount smaller than the above dosage may be sufficient or may exceed the range.

  In addition, the form of these present pharmaceutical compositions is applied to various forms of quasi-drugs including external preparations, oral preparations for beverages, and the like.

(Food composition)
The present platelet aggregation inhibitor can be a food composition for ingestion for food or nutritional supplementation. According to the present food composition, the present blood aggregation inhibitor can be easily and continuously ingested. Therefore, for patients with various diseases including thrombosis associated with platelet aggregation, It is effective in suppressing progression, improving symptoms, and improving QOL. For healthy individuals, it is effective in preventing various vascular diseases and maintaining or improving health. The various vascular diseases mentioned here include various vascular diseases similar to those described in the pharmaceutical composition.

  The food composition can take various forms. That is, it can take the form of various known foods (including processed foods), beverages, seasonings, etc., or the form of its raw materials, as well as powders, granules, tablets, capsules, extracts, liquids (for beverages) Supplemental forms that are mainly oral nutrients or their raw materials, tube feeding nutritional forms that are supplied to the stomach, intestines, and blood vessels via tubes or the like, or their raw materials.

  The content of the present blood aggregation inhibitor (the dry solid content of the extract) in the food composition is not particularly limited, but is preferably 0.000001% by weight or more, more preferably 0.00001-100% by weight. it can. In addition, the present food composition is preferably such that the active ingredient contained therein is preferably 0.0001 to 100 mg / kg body weight, more preferably 0.001 to 10 mg / kg body weight per day for an adult. Can be ingested. In addition, since the intake amount varies depending on various conditions in addition to the type of blood aggregation inhibitor to be used, an amount smaller than the above intake amount may be sufficient, or may be necessary beyond the above range.

(Treatment or prevention method, etc.)
Based on the use form of the present platelet aggregation inhibitor, the present pharmaceutical composition, and the present food composition as described above, as another form of the present invention, any of the present platelet aggregation inhibitor, the present pharmaceutical composition, and the present food composition. There is provided a method for preventing or treating thrombosis or various vascular diseases caused by this, which comprises the step of supplying the present platelet aggregation inhibitor to be administered or ingested to humans.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated further more concretely, this invention is not limited to these Examples at all.

  For 74 types of fresh herbs shown in FIGS. 1 and 2 (extraction operation started within 24 hours after harvesting), if there is no particular description, the leaf part is specified, if specified in parenthesis, 5 g of the portion was weighed, thoroughly stirred with a homogenizer and ground with ethanol, filtered, and the residue was washed with ethanol, and the filtrate and the washing solution were combined to 50 ml. Using this ethanol extract (fresh herb 100 mg / ml), the platelet aggregation inhibitory ability was tested.

  The platelet aggregation inhibitory ability was measured using human blood. 20 μl of each herb extract was added as a test solution to 200 μl of human blood collected from citric acid and stirred at 37 ° C. for 3 minutes. After stirring, ADP is added as an aggregation-inducing substance so as to have four different final concentrations (for example, the ADP concentration is selected from 1, 2, 4, 8, 12, and 16 μM) depending on the blood state. Then, after 2 minutes, blood was sucked with a micromesh filter and the suction pressure was measured. For the measurement, an aspiration type platelet aggregation measuring device (WBA analyzer, manufactured by MC Medical Co., Ltd.) corresponding to whole blood was used. Citric acid blood was collected by collecting 4.5 ml of blood in a syringe prefilled with 0.5 ml of a 3.13% citric acid solution.

The determination of the platelet aggregation inhibiting ability utilized the area value (A) in the range surrounded by the blood aggregation curve and the horizontal axis (ADP concentration) shown in FIG. In order to eliminate individual differences among blood samples, the area value (Aasp) of 20 μl of aspirin solution (5 mM) is measured for each blood sample from each blood sample, and the platelet aggregation inhibition rate of aspirin as a platelet aggregation inhibition standard [ (A ₀ -Aasp) / A ₀ × 100 (%), where A ₀ is the area value in the blood aggregation curve when no aggregation inhibitor is added], and the platelet aggregation inhibition rate (%) of aspirin was calculated. . Next, the platelet aggregation inhibition rate (%) of each herb extract as a sample was determined from the area value in the same manner as described above. The ability of herbs to inhibit platelet aggregation was calculated at a ratio where the inhibition rate of platelet aggregation of aspirin was 100. In addition, the platelet aggregation inhibitory ability of each herb is the result of having repeated the test 3 times. These results are shown together in FIG. 1 and FIG.

  As shown in FIGS. 1 and 2, the ability of the herb to inhibit platelet aggregation was not uniform within the same family or within the same genus, but varied depending on the variety. In Lamiaceae containing Basil, only Ruby Basil was outstanding and excellent. In Lavandula, summer lavender, hid coat lavender, French lavender, and Frenchst ecus lavender showed excellent platelet aggregation inhibitory activity, but yellow flower lavender, spike lavender, and English lavender almost showed platelet aggregation inhibitory activity. There wasn't.

  In the mint genus, apple mint, water mint, orange mint, cool mint, spearmint, peppermint showed various platelet aggregation inhibitory effects, whereas eau de cologne and pineapple did not show aggregation inhibitory effects. In addition, Lamiaceae bush mint (Prostella sp.), Which is not a mint genus but has a mint scent, exhibited an inhibitory effect on platelet aggregation.

  In rosemary belonging to the genus genus rose, both rosemary scanna blue and rosemary dry blue showed good platelet aggregation inhibitory action.

  As for other Lamiaceae herbs, lemon thyme, lemon balm, oregano, bergamot (leaves), hyssop (leaves), and cherry sage have good platelet aggregation inhibitory effects, while sweet marjoram, ramsyear, bergamot (flowers), hyssop (flowers) ), Pineapple sage, amethyst sage, and clary sage exhibited weak or very weak platelet aggregation inhibitory action or platelet aggregation promoting action.

  In the Euphoridae family, both Apple Eucalyptus and Lemon Eucalyptus showed good platelet aggregation inhibitory action, and in the Rosaceae family, wild strawberry and salad burnet were good.

  In the Asteraceae, Stevia, Roman Chamomile, Common Yarrow, and Russian Tarragon were good, but Echinacea (leaves, stems, roots) and chicory promoted aggregation even though they had almost no platelet aggregation inhibitory effect. Also, the common soap of Nadesicoaceae was good. Sweet herbal mexicans were good in the urchinaceae, but lemon verbena had no platelet aggregation inhibitory effect.

  In addition, Gramineae (Lemongrass), Celticaceae (Dill, Fennel, Chervil), Nozenhalenaceae (Nastatium), Aoiaceae (Common Mallow, Black Mallow), Lilyaceae (Chives, Chives (Roots)), Tadeaceae ( Rhubarb), Murasakie (Common Comfrey), Brassicaceae (Wild Rocket), Pleurotus (Common Marein (leaf, fruit)), and Owlaceae (Rose geranium) did not show a good platelet aggregation inhibitory action.

  From the above results, the platelet aggregation inhibitory action in the herb extract varies greatly among varieties, and even within the same genus, there are herbs that have platelet aggregation inhibitory action depending on the variety, but there is almost no platelet aggregation inhibitory action on platelets. In some cases, there are herbs that exert an aggregation-promoting action (Lamiaceae, in particular, Amaryllidae, Labandula, Dianthus and Asteraceae). From these facts, even if the herbal extract of a variety of herbs has an inhibitory effect on platelet aggregation, it cannot be said that the herbs of the variety included in the genus or family in which the variety is included have an inhibitory effect on platelet aggregation. I understood.

  In Example 2, based on the results of Example 1, 23 kinds of herbs exhibiting a good platelet aggregation inhibitory action were obtained by diluting each extract twice with ethanol and diluting the platelets under the same conditions. Inhibitory ability was measured. The results are shown in FIG.

  As shown in FIG. 4, among these 23 types, Hidd Coat Lavender, Lemon Eucalyptus, Stevia, Bergamot, Hyssop, Common Soap Wart, and Salad Barnet exhibited superior platelet aggregation inhibitory ability compared to others. . From the above, it was found that among the 74 kinds of Example 1, these 7 kinds of herbs have a stronger ability to suppress platelet aggregation.

The table | surface which shows the herb used for Example 1, and its platelet aggregation inhibitory ability. The table | surface which shows the herb used for Example 1, and its platelet aggregation inhibitory ability. The figure which shows an example of a blood aggregation curve. The table | surface which shows the herb used for Example 2, and its platelet aggregation inhibitory ability.

Claims (15)

  Ruby Basil, Summer Lavender, Hidcote Lavender, French Stoechas Lavender, Apple Mint, Orange Mint, Orange Mint, Water Mint ), Cool Mint, Spear Mint, Pepper Mint, Rosemary Tuscanablue, Rosemary Dreamy blue, Lemon Thyme, Lemon Balm Balm, Oregano, Bergamot, Hyssop, Cherry Sage, Apple Eucalyptus, Lemon Eucalyptus, Wild Strawberry, Salad Burnet ), Swee 1 selected from the group consisting of Sweet Herb Mexican, Stevia, Roman Chamomile, Common Yarrow, Russian Tarragon and Common Soapwort A platelet aggregation inhibitor comprising a seed or two or more kinds of plants or an extract thereof as an active ingredient.   The plants are Hidcote Lavender, Bergamot, Hyssop, Apple Eucalyptus, Lemon Eucalyptus, Salad Burnet, Stevia and Common. 2. The platelet aggregation inhibitor according to claim 1, wherein the platelet aggregation inhibitor is selected from common soaps.   The plants include Ruby Basil, Summer Lavender, Hidcote Lavender, French Stoechas Lavender, Apple Mint, Orange Mint, Water Mint, Cool Mint, Spear Mint, Pepper Mint, Rosemary Tuscanablue, Rosemary Dreamy blue, Lemon Thyme ), Lemon Balm, Oregano, Bergamot, Hyssop, Cherry Sage, and the platelet aggregation inhibitor according to claim 1.   The platelet aggregation inhibitor according to claim 3, wherein the plant is selected from Hidcote Lavender, Bergamot, and Hyssop.   The platelet aggregation inhibitor according to claim 1, wherein the plant is selected from Wild Strawberry and Salad Burnet.   The platelet aggregation inhibitor according to claim 1, wherein the plant is selected from Apple Eucalyptus and Lemon Eucalyptus.   The platelet aggregation inhibitor according to claim 1, wherein the plant is Sweet Herb Mexican.   The platelet aggregation inhibitor according to claim 1, wherein the plant is Stevia.   The platelet aggregation inhibitor according to any one of claims 1 to 8, wherein the extract is a lower alcohol extract.   The platelet aggregation inhibitor according to claim 9, wherein the extraction solvent is ethanol.   The platelet aggregation inhibitor according to any one of claims 1 to 8, wherein the extract is hot water, water, or a water / organic solvent mixed liquid extract.   The platelet aggregation inhibitor according to any one of claims 1 to 11, wherein a plant after harvest and before drying is used as the plant.   The platelet aggregation inhibitor according to any one of claims 1 to 12, wherein the platelet aggregation inhibitor exhibits a platelet aggregation inhibitory action expressed using adenosine diphosphate (ADP) as an aggregation inducer. A food composition comprising:
A food composition comprising the platelet aggregation inhibitor according to any one of claims 1 to 13.   A pharmaceutical composition for treating or preventing a disease effective for inhibiting platelet aggregation, comprising an effective amount of the platelet aggregation inhibitor according to any one of claims 1 to 13.